Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ProteoSys
Mainz, Germany
- Ownership
- Private
- Employees
- ~2
- Development stage
- Other
01
Overview
ProteoSys is a German biotechnology research company specializing in cell biology and proteomics. It has developed novel biomarkers such as Annexin 3 for non-invasive diagnosis of prostate cancer, aiming to reduce unnecessary biopsies by providing more specific confirmatory tests. The company has also worked on projects related to breast cancer, neurodegenerative diseases, and embryo toxicity testing systems. A key partnership with bioMérieux was established to develop a urine-based diagnostic test using their proprietary ANXA 3 biomarker technology.
- Therapeutic areas
- OncologyNeurologyWomen's Health
- Modalities
- Diagnostic testBiomarker-based diagnostics
- Industry
- Protein Biomarker Diagnostics
02
Partnerships
bioMérieux – license/development agreement for ANXA 3 prostate cancer diagnostic test development on VIDAS® platform.
Beyond the preview
Go deeper on ProteoSys.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProteoSys.